Source: Eur Respir J 2011; 38: 1328-1335
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bakker E.M., Volpi S., Salonini E., van der Wiel-Kooij E.C., Sintnicolaas C.J.J.C.M., Hop W.C.J., Assael B.M., Merkus P.J.F.M., Tiddens H.A.W.M.. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011; 38: 1328-1335

Member's Comments

No comment yet.

Related content which might interest you: The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis Source: Eur Respir J 2011; 37: 806-812 Year: 2011 Combination of electronically controlled breathing pattern and improved nebulizer technology for inhaled corticosteroid therapy of severe asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Successful conversion of patients using nebulised iloprost from multisonic nebuliser to adaptive aerosol delivery nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007 Delivery of dornase alfa via breath-actuated nebulizer: In-vitro measures of performance Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children Source: Eur Respir J 2003; 21: 1007-1011 Year: 2003 Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination Source: Annual Congress 2007 - ISAM - Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination Year: 2007 Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Nebulised antibiotics with the I-neb adaptive aerosol delivery (AAD) system: Impact on adherence in cystic fibrosis (CF) patients Source: Annual Congress 2012 - Cystic fibrosis (adults and children): risk factors and clinical problems Year: 2012 Improvement of small airway deposition of corticosteroids by smart nebulisation Source: International Congress 2018 – Asthma and drugs Year: 2018 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Selection of the optimal nebulizer for further clinical development of inhaled nebulized nitrite (AIR001) in pulmonary arterial hypertension patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 Small airway function in asthma patients treated with an ultrafine inhaled steroid aerosol Source: Eur Respir J 2004; 24: Suppl. 48, 581s Year: 2004 High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014